Related Experiment Video
Updated: Aug 16, 2026

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Association of Plasma Myeloperoxidase with Inflammation and Diabetic status in HFpEF
Sibille Lejeune1, Audrey Ginion1, Nassiba Menghoum1
1Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc and Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, 1200 Brussels, Belgium.
Background:
Inflammation and oxidative stress are thought to play an important role in the pathophysiology of heart failure with preserved ejection fraction (HFpEF) through the development of endothelial dysfunction. Myeloperoxidase (MPO) functions as a link between oxidative stress and inflammation and is an interesting therapeutic target. The objective of this observational cohort study was to compare MPO levels between HFpEF and old controls, to define clinical characteristics associated with high levels of MPO and to assess the relation between MPO levels and vascular function.
Methods:
Patients with HFpEF (N = 55) and controls 60 years (N = 18) were prospectively included. All subjects underwent complete echocardiography and blood sampling. MPO levels were dosed by ELISA assay. Effective arterial elastance (Ea) and peripheral arterial tonometry (EndoPAT reactive hyperemia index RHI and augmentation index AIx) were used to assess vascular function. Characteristics between groups defined by the median of MPO were compared using independent samples t-test or chi square test.
Results:
Patients with HFpEF (80 8.7 years, 65% female) had higher levels of MPO compared to controls (75 5.0 years, 72% female) (34.7 ng/mL [22.7; 44.0] vs 22.6 [18.2; 32.0], p = 0.026). MPO levels were correlated with markers of inflammation; C-reactive protein (Pearson's R = 0.46, p = 0.001) and neutrophile to lymphocyte ratio (R = 0.36, p = 0.031) and with signs of left ventricular (LV) remodelling and elevated filling pressures, namely NT-proBNP levels (R = 0.32, p = 0.019), decreased LV ejection fraction (LVEF, R = -0.36, p = 0.008) and E/e' ratio (R = 0.35, p = 0.011). HFpEF patients with levels of MPO above the median were more often men (48% vs 21%, p = 0.037) and suffered more often from diabetes (48% vs 18%, p = 0.017). Intriguingly, they had lower indices of vascular stiffness (augmentation index 11.1 [0.1; 30.7] vs 19.9 [10.5; 33.4], p = 0.018 and arterial elastance Ea 2.06 0.676 vs 2.43 0.721, p = 0.065) and there was no difference in endothelial function (1.82 [1.34; 2.30] vs 1.66 [1.32; 1.95], p = 0.55).
Conclusions:
HFpEF patients have higher levels of MPO than controls, reflecting leukocyte activation and oxidative stress. Among patients, high levels of MPO are associated with male sex, diabetic status, subtle left ventricular dysfunction and pronounced diastolic dysfunction. The association between oxidative stress and vascular stiffness, on the other hand could not be demonstrated.
Clinical Trial Registration:
Clinical trial NCT03197350.
Insights
Heart failure with preserved ejection fraction (HFpEF) patients exhibit elevated myeloperoxidase (MPO) levels, linked to inflammation and oxidative stress. High MPO correlates with specific clinical factors but not vascular stiffness in HFpEF.
Area of Science:
- Cardiovascular Medicine
- Biomarkers
- Inflammation and Oxidative Stress
Background:
- Inflammation and oxidative stress are implicated in heart failure with preserved ejection fraction (HFpEF) pathophysiology.
- Myeloperoxidase (MPO) bridges oxidative stress and inflammation, presenting a potential therapeutic target.
- Endothelial dysfunction is a key feature in HFpEF development.
Purpose of the Study:
- To compare MPO levels between HFpEF patients and older controls.
- To identify clinical characteristics associated with elevated MPO levels in HFpEF.
- To evaluate the relationship between MPO levels and vascular function in HFpEF.
Main Methods:
- Observational cohort study including 55 HFpEF patients and 18 controls.
- Assessment of MPO levels using ELISA.
- Evaluation of vascular function via effective arterial elastance (Ea) and peripheral arterial tonometry (EndoPAT).
Main Results:
- HFpEF patients showed significantly higher MPO levels compared to controls (p=0.026).
- MPO levels correlated with inflammation markers (CRP, neutrophil-to-lymphocyte ratio) and indicators of diastolic dysfunction (NT-proBNP, E/e').
- Higher MPO levels in HFpEF were associated with male sex and diabetes, but not with reduced endothelial function or increased vascular stiffness.
Conclusions:
- Elevated MPO levels in HFpEF reflect leukocyte activation and oxidative stress.
- High MPO is linked to male sex, diabetes, and diastolic dysfunction in HFpEF.
- The study did not demonstrate a link between MPO-related oxidative stress and vascular stiffness in this cohort.
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies

